Regulatory Victories Meet Commercial Headwinds: Myomo Sits at an Inflection Point in MedTech
Overview
Myomo holds a monopoly in wearable upper limb orthoses with its FDA-cleared MyoPro, but the commercial path has proven far more turbulent than the regulatory journey. The company's rapid revenue surge and profit improvement post-CMS reclassification (early 2024) has given way to pipeline friction and a material guidance cut in 2025 stemming from the inefficiency of direct-to-consumer lead generation and tightening insurance authorization standards. Myomo now faces a liquidity squeeze, exacerbated by a shrinking sales funnel and persistent cost structure, yet management and insiders are doubling down with open market share purchases. The investment opportunity here is highly asymmetric: while the market is pricing in distress and potential insolvency, a successful pivot to a more efficient referral- and clinic-driven model could yield powerful upside thanks to the company’s high-margin, regulatory-protected business model.